Finoriq research workspace
Immunovant, Inc. (IMVT) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Immunovant, Inc. (IMVT).
Company Snapshot
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Company
- Immunovant, Inc. (IMVT)
- Ticker
- IMVT
- Market Cap
- $8.2B
- Latest Price
- $39.91
- Industry
- Biotech & Pharma
Immunovant, Inc. (IMVT) Recent Insider Transactions
Recent market insider transaction records indexed for Immunovant, Inc. (IMVT).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Girao TiagoChief Financial Officer | S | Disposed | -$763,011 | 2026-04-23 |
| Stout Jay SChief Technology Officer | S | Disposed | -$81,573 | 2026-04-23 |
| Gloria MelanieChief Operating Officer | S | Disposed | -$216,567 | 2026-04-08 |
| Van Tuyl ChristopherChief Legal Officer | S | Disposed | -$128,247 | 2026-04-08 |
| Stout Jay SChief Technology Officer | S | Disposed | -$213,886 | 2026-04-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.